A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer.

Trial Profile

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Margetuximab (Primary) ; Pembrolizumab
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MacroGenics
  • Most Recent Events

    • 03 May 2017 According to a MacroGenics media release, company expects to complete enrollment of this study in 2017.
    • 04 Apr 2017 Planned number of patients changed from 52 to 72.
    • 04 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top